Uncategorized
Persica Pharmaceuticals Announces Collaboration with BackCare
Persica Pharmaceuticals Announces Collaboration with BackCare London, UK, 24 August 2022 – Persica Pharmaceuticals Ltd, a clinical stage pharmaceutical company developing a breakthrough injectable antibiotic formulation to treat patients suffering from chronic low back pain (cLBP), today announces a new collaboration with BackCare, a charity dedicated to back pain, regardless of cause. The two organisations share a goal to provide
Peter Hamlyn, Founder and Director of Persica Pharmaceuticals will be presenting at the British Association of Spine Surgeons
Peter Hamlyn, Founder and Director of Persica Pharmaceuticals will be presenting at the British Association of Spine Surgeons London, UK, 24 March 2022 – Persica Pharmaceuticals Ltd, a clinical stage pharmaceutical company developing a breakthrough injectable antibiotic formulation, PP353, to treat patients suffering from chronic Low Back Pain (cLBP), today announces that Peter Hamlyn, founding member and Non-Executive Director
European Patent Office has granted Persica’s first patent
European Patent Office has granted Persica’s first patent London, UK, 03 February 2022 – Persica is delighted to announce that the European Patent Office has granted Persica’s first patent “Antibiotic Formulations for Lower Back Pain – EP3541442” which provides a foundation for our intellectual property. Persica’s novel antibiotic formulation for intradiscal administration of antibiotic to treat patients with chronic Lower